Robert Brown to Treatment Outcome
This is a "connection" page, showing publications Robert Brown has written about Treatment Outcome.
Connection Strength
0.088
-
Shneider NA, Harms MB, Korobeynikov VA, Rifai OM, Hoover BN, Harrington EA, Aziz-Zaman S, Singleton J, Jamil A, Madan VR, Lee I, Andrews JA, Smiley RM, Alam MM, Black LE, Shin M, Watts JK, Walk D, Newman D, Pascuzzi RM, Weber M, Neuwirth C, Da Cruz S, Soriano A, Lane R, Henry S, Mathews J, Jafar-Nejad P, Norris D, Rigo F, Brown RH, Miller S, Crean R, Bennett CF. Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series. Lancet. 2025 Jun 07; 405(10494):2075-2086.
Score: 0.029
-
Lindborg SR, Goyal NA, Katz J, Burford M, Li J, Kaspi H, Abramov N, Boulanger B, Berry JD, Nicholson K, Mozaffar T, Miller R, Jenkins L, Baloh RH, Lewis R, Staff NP, Owegi MA, Dagher B, Blondheim-Shraga NR, Gothelf Y, Levy YS, Kern R, Aricha R, Windebank AJ, Bowser R, Brown RH, Cudkowicz ME. Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes. Muscle Nerve. 2024 Jun; 69(6):719-729.
Score: 0.027
-
Fournier CN, Schoenfeld D, Berry JD, Cudkowicz ME, Chan J, Quinn C, Brown RH, Salameh JS, Tansey MG, Beers DR, Appel SH, Glass JD. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018 05; 19(3-4):242-249.
Score: 0.017
-
Weiss MD, Macklin EA, Simmons Z, Knox AS, Greenblatt DJ, Atassi N, Graves M, Parziale N, Salameh JS, Quinn C, Brown RH, Distad JB, Trivedi J, Shefner JM, Barohn RJ, Pestronk A, Swenson A, Cudkowicz ME. A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. Neurology. 2016 Apr 19; 86(16):1474-81.
Score: 0.015